ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions
View by Date

Monday, November 6, 2017

9:00AM-11:00AM
Abstract Number: 1289
Assessing ACR/EULAR Provisional 2017 Classification Criteria for Granulomatosis with Polyangiitis (GPA) in a Cohort of 376 Children with Small to Medium Vessel Chronic Vasculitis – a Pediatric Vasculitis Initiative (PedVas) Study
Pediatric Rheumatology – Clinical and Therapeutic Aspects Poster II: Lupus and Related Disorders, Myositis, Scleroderma and Vasculitis
9:00AM-11:00AM
Abstract Number: 1060
Assessing Interferon Regulatory Factor 5 (IRF5) Function in Human Primary Immune Cells with Cell-Penetrating Peptides
Innate Immunity and Rheumatic Disease Poster II
9:00AM-11:00AM
Abstract Number: 1282
Assessing the Prevalence of Juvenile Systemic Sclerosis in Childhood Using Administrative Claims Data from the United States
Pediatric Rheumatology – Clinical and Therapeutic Aspects Poster II: Lupus and Related Disorders, Myositis, Scleroderma and Vasculitis
9:00AM-11:00AM
Abstract Number: 1362
Assessing the Quality, Reliability and Readability of Online Health Information Regarding Rheumatoid Arthritis
Rheumatoid Arthritis – Clinical Aspects Poster II: Pathophysiology, Autoantibodies, and Disease Activity Measures
9:00AM-11:00AM
Abstract Number: 1615
Assessment of a Cognitive Impairment Measure in Systemic Lupus Erythematosus
Systemic Lupus Erythematosus – Clinical Aspects and Treatment Poster II: Damage and Comorbidities
9:00AM-11:00AM
Abstract Number: 1648
Assessment of Outcome in Lupus Nephritis Patients: A Retrospective Analysis of a Single Center Cohort over 20 Years
Systemic Lupus Erythematosus – Clinical Aspects and Treatment Poster II: Damage and Comorbidities
9:00AM-11:00AM
Abstract Number: 1106
Association between ABCG2 rs2231142 and Poor Response to Allopurinol: Replication and Meta-Analysis
Metabolic and Crystal Arthropathies Poster I
9:00AM-11:00AM
Abstract Number: 1484
Association between Primary Sjogren’s Syndrome, Arterial Stiffness and Subclinical Atherosclerosis: A Systematic Review and Meta-Analysis
Sjögren's Syndrome Poster II: Clinical Research
9:00AM-11:00AM
Abstract Number: 1485
Association between Primary Sjogren’s Syndrome, Cardiovascular and Cerebrovascular Events: A Systematic Review and Meta-Analysis
Sjögren's Syndrome Poster II: Clinical Research
9:00AM-11:00AM
Abstract Number: 999
Association between Smoking with Spinal Level of Stiffness and Functional Limitation in Patients with Axial Spondyloarthritis: Results from the Spanish Atlas
Epidemiology and Public Health Poster II: Rheumatic Diseases Other than Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 1028
Association of a Non-Synonymous, Loss-of-Function, Variant in NOD2 with Reduced Tissue Damage in ACPA +Ve RA
Genetics, Genomics and Proteomics Poster II
9:00AM-11:00AM
Abstract Number: 1751
Association of a TNFSF4 Upstream Region Single Nucleotide Polymorphism with Susceptibility to Proteinase 3-ANCA Positive Vasculitis in a Japanese Population
Vasculitis Poster II: ANCA-Associated Vasculitis
9:00AM-11:00AM
Abstract Number: 1226
Association of Dorsal Flat Vertebra/Platyspondylia As a Form of Vertebral Dysplasia within Type II Collage Disorders
Osteoporosis and Metabolic Bone Disease – Clinical Aspects and Pathogenesis Poster II
9:00AM-11:00AM
Abstract Number: 1762
Association of ETS1 Polymorphism in 3’ Untranslated Region with Susceptibility to Granulomatosis with Polyangiitis and Proteinase 3-ANCA Positive Vasculitis in a Japanese Population
Vasculitis Poster II: ANCA-Associated Vasculitis
9:00AM-11:00AM
Abstract Number: 977
Association of Leisure-Time Physical Activity with Late-Life Mobility Limitation Among Women with Total Joint Replacement for Hip or Knee Osteoarthritis
Epidemiology and Public Health Poster II: Rheumatic Diseases Other than Rheumatoid Arthritis
  • «Previous Page
  • 1
  • …
  • 4
  • 5
  • 6
  • 7
  • 8
  • …
  • 65
  • Next Page»
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology